---
title: "Foghorn Therapeutics (FHTX) Receives a Buy from Stifel Nicolaus"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284219797.md"
description: "Stifel Nicolaus analyst Laura Prendergast has maintained a Buy rating on Foghorn Therapeutics (FHTX) with a price target of $12.00. Prendergast, a 5-star analyst, has an average return of 59.6% and a success rate of 61.90%. The analyst consensus for Foghorn Therapeutics is Strong Buy, with a price target consensus of $11.67."
datetime: "2026-04-27T12:45:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284219797.md)
  - [en](https://longbridge.com/en/news/284219797.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284219797.md)
---

# Foghorn Therapeutics (FHTX) Receives a Buy from Stifel Nicolaus

Stifel Nicolaus analyst Laura Prendergast maintained a Buy rating on Foghorn Therapeutics today and set a price target of $12.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Prendergast is a 5-star analyst with an average return of 59.6% and a 61.90% success rate. Prendergast covers the Healthcare sector, focusing on stocks such as Erasca, BridgeBio Oncology Therapeutics, and Revolution Medicines.

Foghorn Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $11.67.

### Related Stocks

- [FHTX.US](https://longbridge.com/en/quote/FHTX.US.md)
- [SF.US](https://longbridge.com/en/quote/SF.US.md)
- [ERAS.US](https://longbridge.com/en/quote/ERAS.US.md)
- [BBIO.US](https://longbridge.com/en/quote/BBIO.US.md)
- [RVMD.US](https://longbridge.com/en/quote/RVMD.US.md)
- [SF-C.US](https://longbridge.com/en/quote/SF-C.US.md)
- [SFB.US](https://longbridge.com/en/quote/SFB.US.md)
- [SF-B.US](https://longbridge.com/en/quote/SF-B.US.md)
- [SF-D.US](https://longbridge.com/en/quote/SF-D.US.md)
- [RVMDW.US](https://longbridge.com/en/quote/RVMDW.US.md)

## Related News & Research

- [Foghorn Therapeutics (FHTX) Receives a Buy from H.C. Wainwright](https://longbridge.com/en/news/285715134.md)
- [Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Short Interest Update](https://longbridge.com/en/news/294357729.md)
- [This Analyst Just Cut Its Price Target on SNDK Stock. Here's Why.](https://longbridge.com/en/news/293654906.md)
- [Karyopharm says Phase 3 selinexor maintenance trial in endometrial cancer misses PFS endpoint](https://longbridge.com/en/news/294410278.md)
- [ADAR1 Capital Management LLC Grows Stock Position in Relmada Therapeutics, Inc. $RLMD](https://longbridge.com/en/news/294166619.md)